Wengui Yu, MD
Neurocritical Care · Orange, CANPI 1225104193
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Amgen accounts for 61.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $20,571 and has fallen 99.9% since, to $30 in 2023. Among neurocritical care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $1024.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13K
- Stryker$7K
- Penumbra, Inc.$800
- Viz.ai, Inc.$122
- Johnson & Johnson$116
- Portola Pharmaceuticals, LLC$24
- plus $30 from 2 others
Across 5 payments — averaging $9796.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$48K
- Stryker$900
What the payments were for
- Consulting fees$10,67550%
- Travel & lodging$10,38348%
- Food & beverage$4652%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $13,239 |
| Stryker | 7 | $7,193 |
| Penumbra, Inc. | 2 | $800 |
| Viz.ai, Inc. | 1 | $122 |
| Johnson & Johnson | 1 | $116 |
| Portola Pharmaceuticals, LLC | 1 | $24 |
| Microtransponder, Inc. | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$13,066
- WINGSPAN$7,182
- Penumbra System$800
- Viz.AI LVO$122
- EMBOTRAP II Revascularization Device$116
How this compares
$21,524 in reported general payments places this provider in the 95th percentile of 65 neurocritical care providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $18,071 |
| Lacosamide | 15 | $3,186 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $1,357 |
| Levetiracetam | 20 | $949 |
| Atorvastatin Calcium | 101 | $852 |
| Gabapentin | 45 | $473 |
| ClopidogrelClopidogrel Bisulfate | 42 | $386 |
| Rosuvastatin Calcium | 18 | $292 |
| Tramadol Hcl | 13 | $193 |
| Lorazepam | 12 | $174 |
| Donepezil Hcl | 11 | $155 |
| Benazepril Hcl | 16 | $127 |
| Amlodipine Besylate | 22 | $110 |
| Losartan Potassium | 11 | $38 |
| Metformin Hcl | 14 | $6 |
Paid to pharmacies, not to this prescriber.
Other neurocritical care in Orange
- Shahab KhazanehdariOrange$963
- Anirudha RathnamOrange$835
- Angud MehdiOrange$416
- Imad KhanOrange$118
- Ahmad Riad RamadanOrange$88
- Cyrus DasturOrange$34
- Nerses SanossianLos Angeles$106K
- May Kim-TenserLos Angeles$29K
- Marion BuckwalterStanford$20K
- Johannes Pulst-KorenbergLos Angeles$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.